These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 16972907)

  • 1. A vision of cell death: Fas ligand and immune privilege 10 years later.
    Ferguson TA; Griffith TS
    Immunol Rev; 2006 Oct; 213():228-38. PubMed ID: 16972907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of Fas ligand in immune privilege.
    Green DR; Ferguson TA
    Nat Rev Mol Cell Biol; 2001 Dec; 2(12):917-24. PubMed ID: 11733771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vision of cell death: insights into immune privilege.
    Ferguson TA; Griffith TS
    Immunol Rev; 1997 Apr; 156():167-84. PubMed ID: 9176707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Fas ligand and TNF-related apoptosis-inducing ligand (TRAIL) in the ocular immune response.
    Ferguson TA; Griffith TS
    Chem Immunol Allergy; 2007; 92():140-154. PubMed ID: 17264490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular autoimmunity: the price of privilege?
    Caspi RR
    Immunol Rev; 2006 Oct; 213():23-35. PubMed ID: 16972894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune privilege in the anterior chamber of the eye.
    Niederkorn JY
    Crit Rev Immunol; 2002; 22(1):13-46. PubMed ID: 12186187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. See no evil, hear no evil, do no evil: the lessons of immune privilege.
    Niederkorn JY
    Nat Immunol; 2006 Apr; 7(4):354-9. PubMed ID: 16550198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas ligand exerts its pro-inflammatory effects via neutrophil recruitment but not activation.
    Dupont PJ; Warrens AN
    Immunology; 2007 Jan; 120(1):133-9. PubMed ID: 17233740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apoptosis in mammalian eye development: lens morphogenesis, vascular regression and immune privilege.
    Lang RA
    Cell Death Differ; 1997 Jan; 4(1):12-20. PubMed ID: 16465205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune deviation in relation to ocular immune privilege.
    Streilein JW; Ksander BR; Taylor AW
    J Immunol; 1997 Apr; 158(8):3557-60. PubMed ID: 9103414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune regulation and the eye.
    Stein-Streilein J
    Trends Immunol; 2008 Nov; 29(11):548-54. PubMed ID: 18838303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors.
    Mrass P; Weninger W
    Immunol Rev; 2006 Oct; 213():195-212. PubMed ID: 16972905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance.
    Griffith TS; Yu X; Herndon JM; Green DR; Ferguson TA
    Immunity; 1996 Jul; 5(1):7-16. PubMed ID: 8758890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of ocular immune responses.
    Streilein JW
    Eye (Lond); 1997; 11 ( Pt 2)():171-5. PubMed ID: 9349408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. History and physiology of immune privilege.
    Niederkorn JY; Stein-Streilein J
    Ocul Immunol Inflamm; 2010 Jan; 18(1):19-23. PubMed ID: 20128645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell death and immune privilege.
    Ferguson TA; Green DR; Griffith TS
    Int Rev Immunol; 2002; 21(2-3):153-72. PubMed ID: 12424841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune privilege or inflammation? Insights into the Fas ligand enigma.
    O'Connell J; Houston A; Bennett MW; O'Sullivan GC; Shanahan F
    Nat Med; 2001 Mar; 7(3):271-4. PubMed ID: 11231613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fas-ligand and immune privilege: the eyes have it.
    Ferguson TA; Green DR
    Cell Death Differ; 2001 Jul; 8(7):771-2. PubMed ID: 11464222
    [No Abstract]   [Full Text] [Related]  

  • 19. Tissue barriers, immunosuppressive microenvironments, and privileged sites: the eye's point of view.
    Streilein JW
    Reg Immunol; 1993; 5(5):253-68. PubMed ID: 8148235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Privilege revisited: an evaluation of the eye's defence mechanisms.
    Forrester JV
    Eye (Lond); 2009 Apr; 23(4):756-66. PubMed ID: 18989350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.